Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor that covalently binds Cys481 in BTK’s ATP-binding pocket. It demonstrates potent efficacy in CLL models and features an alkyne group for CuAAC click chemistry reactions. Reagent grade, for research purpose.
Usually ships within 24 hours.